SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events
16 references·0 citing·47 second hop
A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events (2013)A Systematic Review of Utility Values for…Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals (2011)Utility values in National In…Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study (2010)Population preference values …Societal preference values for advanced melanoma health states in the United Kingdom and Australia (2009)Societal preference values fo…Methods for Measuring Temporary Health States for Cost-Utility Analyses (2009)Methods for Measuring Tempora…Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment (2009)Determination of quality of l…An updated systematic review of Health State Utility Values for osteoporosis related conditions (2009)An updated systematic review …Health state utilities for non small cell lung cancer (2008)Health state utilities for no…International society for pharmacoeconomics and outcomes research (2006)International society for pha…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK (2001)Cost Effectiveness of Treatme…Valuing Health-Related Quality of Life (2000)Valuing Health-Related Qualit…One Thousand Health-Related Quality-of-Life Estimates (2000)One Thousand Health-Related Q…Utility Valuations for Outcome States of Colorectal Cancer (1999)Utility Valuations for Outcom…Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast Cancer (1999)Cost-Utility Analysis of Chem…Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Guidelines for authors and pe…A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer (1996)A New Decision Model for Cost…Methods for the economic evaluation of health care programmes (1987)Quality of life and pharmacoeconomics in clinical trials (1996)The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001)Methods for the Economic Evaluation of Health Care Programmes (2005)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Modeling Valuations for EuroQol Health States (1997)Using Health State Utility Values in Models Exploring the Cost-Effectiveness of Health Technologies (2012)Systematic Searching and Selection of Health State Utility Values from the Literature (2013)Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma (2014)EuroQol - a new facility for the measurement of health-related quality of life (1990)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)The MOS 36-ltem Short-Form Health Survey (SF-36) (1992)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making (2004)A review of health utilities using the EQ-5D in studies of cardiovascular disease (2010)Prospect Theory: An Analysis of Decision under Risk (1979)STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT (1986)Prospect theory: An analysis of decision under risk (1988)A comparative review of four preference-weighted measures of health-related quality of life (2003)Comparing preference-based quality-of-life measures: results from rehabilitation patients with musculoskeletal, cardiovascular, or psychosomatic disorders (2008)Discrete Choice Modeling for the Quantification of Health States: The Case of the EQ-5D (2010)Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)Utilities Measured by Rating Scale, Time Trade-off, and Standard Gamble: Review and Reference for Health Care Professionals. (2002)Development of a simulation model of colorectal cancer (2007)A Review and Meta-analysis of Colorectal Cancer Utilities (2014)Measurement of health state utilities for economic appraisal (1986)Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia (2012)Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects (2014)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)The estimation of a preference-based measure of health from the SF-36 (2002)Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC Methods Programme (2006)A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions (2014)Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS (2017)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting (2013)Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer (2018)Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada (2016)Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial (2019)Population Genomic Screening for Three Common Hereditary Conditions (2023)
this work references cited by second hop

References

  • 1996Guidelines for authors and peer reviewers of economic submissions to the BMJ1,828 cited
  • 2000One Thousand Health-Related Quality-of-Life Estimates662 cited
  • 2008Health state utilities for non small cell lung cancer407 cited
  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2000Valuing Health-Related Quality of Life222 cited
  • 1999Utility Valuations for Outcome States of Colorectal Cancer180 cited
  • 2009An updated systematic review of Health State Utility Values for osteoporosis related conditions132 cited
  • 2009Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment126 cited
  • 2010Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study112 cited
  • 2011Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals99 cited
  • 1996A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast Cancer96 cited
  • 2006International society for pharmacoeconomics and outcomes research92 cited
  • 2001Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK86 cited
  • 2009Societal preference values for advanced melanoma health states in the United Kingdom and Australia

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

74 cited
  • 2009Methods for Measuring Temporary Health States for Cost-Utility Analyses60 cited
  • 1999Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast Cancer57 cited
  • Cited by

    No citing works inside the corpus for this window.